STRATEGIC ARRANGEMENTS (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
Aug. 02, 2017 |
Dec. 01, 2007 |
Sep. 30, 2018 |
Sep. 30, 2017 |
Jun. 30, 2018 |
Sep. 30, 2018 |
Sep. 30, 2017 |
Dec. 31, 2017 |
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||
| Minimum annual royalty payment | $ 500,000 | |||||||
| Royalty expense | $ 108,000 | $ 111,000 | ||||||
| CASE | ||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||
| Royalty expense | $ 37,000 | $ 38,000 | ||||||
| Royalty payable | $ 37,000 | $ 37,000 | $ 37,000 | |||||
| Royalty Agreement Terms | CASE | ||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||
| Royalty agreement period | 10 years | 10 years | ||||||
| Minimum annual royalty payment | $ 10,000 | |||||||
| Royalty agreement percentage | 3.00% | |||||||
| Milestone payments for FDA approval to sell our products within the United States | $ 5,000 | |||||||
| Milestone payment for general product launch | $ 10,000 | |||||||